Outcome data for patients with CBF AML with and without KIT mutations
| . | KIT mutation . | WT KIT . | P . | ||
|---|---|---|---|---|---|
| (N = 38) . | Outcome data . | (N = 165) . | Outcome data . | ||
| N . | % ± 2SE % . | N . | % ± 2SE % . | ||
| 5-y OS from study entry | |||||
| All studies | 38 | 76 ± 15 | 165 | 74 ± 8 | .819 |
| POG-9421 | 11 | 64 ± 29 | 37 | 89 ± 12 | .014 |
| CCG-2891 | 5 | 100 ± 0 | 13 | 67 ± 38 | .577 |
| CCG-2961 | 15 | 79 ± 22 | 83 | 68 ± 12 | .701 |
| COG AAML03P1* | 7 | 67 ± 54 | 32 | 77 ± 20 | .589 |
| 5-y EFS from study entry | |||||
| All studies | 38 | 55 ± 17 | 165 | 59 ± 9 | .857 |
| POG-9421 | 11 | 55 ± 30 | 37 | 66 ± 18 | .563 |
| CCG-2891 | 5 | 80 ± 36 | 13 | 53 ± 41 | .925 |
| CCG-2961 | 15 | 57 ± 26 | 83 | 57 ± 12 | .866 |
| COG AAML03P1* | 7 | 44 ± 44 | 32 | 61 ± 21 | .518 |
| 5-y RR from end of induction | |||||
| All studies | 36 | 35 ± 17 | 144 | 34 ± 10 | .877 |
| POG-9421 | 11 | 36 ± 29 | 36 | 35 ± 19 | .961 |
| CCG-2891 | 4 | 0 ± 0 | 13 | 50 ± 41 | .255 |
| CCG-2961 | 14 | 31 ± 26 | 66 | 33 ± 14 | .814 |
| COG AAML03P1* | 7 | 56 ± 44 | 29 | 30 ± 21 | .512 |
| 5-y DFS from induction CR | |||||
| All studies | 36 | 56 ± 18 | 144 | 60 ± 10 | .786 |
| POG-9421 | 11 | 55 ± 30 | 36 | 65 ± 19 | .58 |
| CCG-2891 | 4 | 100 ± 0 | 13 | 50 ± 41 | .541 |
| CCG-2961 | 14 | 54 ± 28 | 66 | 58 ± 14 | .707 |
| COG AAML03P1* | 7 | 44 ± 44 | 29 | 61 ± 22 | .484 |
| . | KIT mutation . | WT KIT . | P . | ||
|---|---|---|---|---|---|
| (N = 38) . | Outcome data . | (N = 165) . | Outcome data . | ||
| N . | % ± 2SE % . | N . | % ± 2SE % . | ||
| 5-y OS from study entry | |||||
| All studies | 38 | 76 ± 15 | 165 | 74 ± 8 | .819 |
| POG-9421 | 11 | 64 ± 29 | 37 | 89 ± 12 | .014 |
| CCG-2891 | 5 | 100 ± 0 | 13 | 67 ± 38 | .577 |
| CCG-2961 | 15 | 79 ± 22 | 83 | 68 ± 12 | .701 |
| COG AAML03P1* | 7 | 67 ± 54 | 32 | 77 ± 20 | .589 |
| 5-y EFS from study entry | |||||
| All studies | 38 | 55 ± 17 | 165 | 59 ± 9 | .857 |
| POG-9421 | 11 | 55 ± 30 | 37 | 66 ± 18 | .563 |
| CCG-2891 | 5 | 80 ± 36 | 13 | 53 ± 41 | .925 |
| CCG-2961 | 15 | 57 ± 26 | 83 | 57 ± 12 | .866 |
| COG AAML03P1* | 7 | 44 ± 44 | 32 | 61 ± 21 | .518 |
| 5-y RR from end of induction | |||||
| All studies | 36 | 35 ± 17 | 144 | 34 ± 10 | .877 |
| POG-9421 | 11 | 36 ± 29 | 36 | 35 ± 19 | .961 |
| CCG-2891 | 4 | 0 ± 0 | 13 | 50 ± 41 | .255 |
| CCG-2961 | 14 | 31 ± 26 | 66 | 33 ± 14 | .814 |
| COG AAML03P1* | 7 | 56 ± 44 | 29 | 30 ± 21 | .512 |
| 5-y DFS from induction CR | |||||
| All studies | 36 | 56 ± 18 | 144 | 60 ± 10 | .786 |
| POG-9421 | 11 | 55 ± 30 | 36 | 65 ± 19 | .58 |
| CCG-2891 | 4 | 100 ± 0 | 13 | 50 ± 41 | .541 |
| CCG-2961 | 14 | 54 ± 28 | 66 | 58 ± 14 | .707 |
| COG AAML03P1* | 7 | 44 ± 44 | 29 | 61 ± 22 | .484 |
CBF AML indicates core binding factor acute myeloid leukemia; WT, wild-type; OS, overall survival; POG, Pediatric Oncology Group; CCG, Children's Cancer Group; COG, Children's Oncology Group; EFS, event-free survival; RR, relapse risk; and DFS, disease-free survival.
Three-year estimates are used because of lack of follow-up.